PTC Therapeutics
South Plainfield · Founded 1998
About PTC Therapeutics
PTC Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of orally administered and small-molecule drugs. It offers Ataluren, an orally administered small-molecule investigational new drug for the treatment of cystic fibrosis and duchenne muscular dystrophy caused by nonsense mutations. The company also provides PTC299, an anti-angiogenesis drug for the treatment of metastatic breast cancer, multiple tumors, and neurofibromatosis. Its products are used for the treatment of genetic disorders, oncology, and infectious diseases. PTC Therapeutics, Inc. was founded in 1998 and is based in South Plainfield, New Jersey.
Company Facts
- Founded: 1998
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 501 – 1,000
- Estimated revenue: $500K – $1M
- Total funding: $1.6B
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2022)
- Ticker: nasdaq:PTCT
- Website: ptcbio.com
- Phone: +1 908 222 7000
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ptc-therapeutics-27835 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.